Determinants of drug survival for etanercept in a long‐term daily practice cohort of patients with psoriasis. (February 2014)

• Record Type: Journal Article
• Authors: van den, J.M.P.A.; van, P.P.M.; Driessen, R.J.B.; van de, P.C.M.; Seyger, M.M.B.; Kievit, W.; de, E.M.G.J.
• Is Part Of: British journal of dermatology. Volume 170:Number 2(2014:Feb.)
• Page Start: 415
• Page End: 424
• Publication Date: 2014-02
• Subjects: Dermatology -- Periodicals; Skin -- Diseases -- Periodicals; 616.5
• DOI: 10.1111/bjd.12648
• Languages: English
• ISSNs: 0007-0963

Abstract

<abstract abstract-type="short" xml:lang="en" id="bjd12648-abs-0002"> <title> <x xml:space="preserve">Abstract</x> </title> <p> <bold>What's already known about this topic?</bold> </p> <p> <list id="bjd12648-list-0001" list-type="bullet"> <list-item> <p>Etanercept has proven to be effective and well tolerated in patients with psoriasis in several randomized controlled trials.</p> </list-item> </list> </p> <p> <bold>What does this study add?</bold> </p> <p> <list id="bjd12648-list-0002" list-type="bullet"> <list-item> <p>This is the first daily practice study calculating drug survival rates of patients treated with etanercept for a maximum observation period of 7·5 years.</p> </list-item> <list-item> <p>Determinants of longer drug survival were calculated for general drug survival, and separately for discontinuation due to adverse events or ineffectiveness of therapy.</p> </list-item> </list> </p> </abstract>